EP Patent

EP0401384B1 — Chemically modified granulocyte colony stimulating factor

Assigned to Amgen K A Inc · Expires 1996-03-13 · 30y expired

What this patent protects

A new chemically modified protein consists of human granulocyte colony stimulating factor (G-CSF) (aminoacid sequence of 174 units ( or 175 with N-terminal methionine) given in the patent) (expressed by host cells from a foreign DNA sequence) bound to polyethylene glycol either t…

USPTO Abstract

A new chemically modified protein consists of human granulocyte colony stimulating factor (G-CSF) (aminoacid sequence of 174 units ( or 175 with N-terminal methionine) given in the patent) (expressed by host cells from a foreign DNA sequence) bound to polyethylene glycol either through the amino gps. of the aminoacid residues or through carboxyl gps.

Drugs covered by this patent

Patent Metadata

Patent number: EP0401384B1
Jurisdiction: EP
Classification: —
Expires: 1996-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Amgen K A Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.